Nantkwest claims efficacy with its most advanced NK cell therapy but, as ever with Patrick Soon-Shiong companies, it’s complicated.
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
Sanofi goes all in on Kiadis's natural killer cell projects, gained through an all-stock deal in 2019.
Shortly after canning its lead and acquiring the NK cell company Cytosen, Kiadis flips part of the tech to Sanofi.
Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.
A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.